Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis
The aim of this study is to compare the efficacy of intralesional bevacizumab, a monoclonal antibody against vascular endothelial growth factor, versus the antiviral drug cidofovir in patients with recurrent respiratory papillomatosis.
Recurrent Respiratory Papillomatosis
DRUG: Bevacizumab|DRUG: Cidofovir|OTHER: Placebo
Changes in the annual surgery rate, Changes in the annual surgery rate before and after intervention, 12 months|Severity of airway affection measured by the Derkay papilloma severity grading scale, Changes in the Derkay papilloma severity grading scale before and after intervention, 12 months
Hoarseness severity measured by the Voice Handicap Index, Changes in the Voice Handicap Index before and after intervention, 12 months|Number of Treatment-Related Adverse Events According to Common Terminology Criteria for Adverse Events (CTCAE), Adverse events, 12 months
The investigators designed a randomized, double-blind, placebo-controlled study. Children and adults will be randomized to receive either 3 dosis of intralesional bevacizumab, cidofovir or saline solution. Primary endpoints are the assessment of changes in the annual surgery rate and Derkay papilloma severity grading scale; secondary endpoints are changes in the Voice Handicap Index and safety.